1. Scrip
  2. >>Business

Mayne Cements Place On US Generics Map

 
• By Sukaina Virji

Asset divestments continue in the lead up to Teva's acquisition of Allergan's generics business.

Mayne Pharma Group Ltd. of Australia has agreed to buy a portfolio of US generic products from Teva Pharmaceutical Industries Ltd. and Allergan PLC for $652m. The portfolio consists of 37 approved products and 5 FDA-filed products in a range of territories and indications.

The two larger companies are making a series of divestments to gain antitrust approval for Teva's acquisition of Allergan's generics business for $40.5bn

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.